Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn

Next issueIssue 16 · Tue 29 Sep

Otsuka

Every issue covering Otsuka.

1 issue

2026-09-22No. 15
The CVR is an option, and Lilly holds it